| Debra Michelle Brewer, ACNS-BC, APN | |
|
1215 Sidney St, Suite 201, Batesville, AR 72501-7203 | |
| (870) 698-9997 | |
| (870) 698-0022 |
| Full Name | Debra Michelle Brewer |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Adult Health |
| Location | 1215 Sidney St, Batesville, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841512969 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | S02248 CNS (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Debra Michelle Brewer, ACNS-BC, APN 1215 Sidney St, Suite 201, Batesville, AR 72501-7203 Ph: (870) 698-9997 | Debra Michelle Brewer, ACNS-BC, APN 1215 Sidney St, Suite 201, Batesville, AR 72501-7203 Ph: (870) 698-9997 |
News Archive
Researchers at the University of Georgia have discovered that a combination of two commonly prescribed drugs used to treat high cholesterol and osteoporosis may serve as the foundation of a new treatment for toxoplasmosis, a parasitic infection caused by the protozoan Toxoplasma gondii. They published their findings recently in PLOS Pathogens.
A drug once used to treat high blood pressure can help alcoholics with withdrawal symptoms reduce or eliminate their drinking, Yale University researchers report Nov. 19 in the American Journal of Psychiatry.
A team of NIBIB-supported bioengineers, aerospace scientists, and cardiovascular clinicians are improving the function of the thousands of life-saving ventricular assist devices (VADs) implanted in advanced heart failure patients each year.
The health insurer WellPoint has announced guidelines for using comparative effectiveness studies to pit drugs against one another and determine which works best, the Indianapolis Business Journal reports. "Congress has also approved $4.1 billion in the past 15 months to fund comparative-effectiveness studies and a new agency that specializes in them.
After a three-day consultation on Zika research and development, international experts, convened by WHO, have agreed on top priorities to advance R&D for Zika medical products.
› Verified 4 days ago